Navigation Links
Weight-Loss Medication Evaluated By Nutrition Expert

A 60 mg low-dose version of the prescription weight-loss medication orlistat (marketed by GlaxoSmithKline as Xenical? 120 mg) was found to be safe, effective and tolerable in overweight individuals,// according to new data presented today at the 2005 Annual Meeting of NAASO, The Obesity Society in Vancouver, British Columbia.

The study, which compared orlistat 60 mg plus diet to placebo plus diet in patients with a body mass index (BMI) of 25 to 28, demonstrates a statistically significant difference in weight loss. Orlistat patients who completed the four-month treatment period lost 5 percent of their baseline weight and diet alone lost 3.3 percent.

The randomized, placebo-controlled, 16-week study was conducted in a primary care setting, offered minimal intervention and was largely self-instructional. Approximately 36 percent of orlistat users and 28 percent of the placebo group (who used diet modifications alone) lost more than five percent of their initial body weight. Approximately 57 percent of orlistat users, compared to 42 percent of the placebo group, lost more than three percent of their initial body weight.

Orlistat patients also demonstrated significant decreases in total cholesterol, LDL cholesterol, systolic and diastolic blood pressure. Safety and tolerability of 60 mg orlistat in this population was similar to that observed in previous studies in a more overweight population.

"Prescription orlistat has been used successfully for years to help obese individuals lose weight and improve their health, so it's exciting to find that a lower dose of orlistat can help those who are overweight with their weight loss efforts," said lead investigator Dr. James Anderson, Professor of Medicine and Clinical Nutrition at the University of Kentucky. "The number of overweight individuals in this country continues to increase each year, and the risk of these folks progressing to obesity - and the resulting more serious med ical problems - is significant."
'"/>




Related medicine news :

1. Weight-Loss Drinks Can Make You Gassy
2. Weight-Loss Surgeries Changing Lives
3. Latest Weight-Loss Pill Offers Modest Results, Blocks Munchies
4. Weight-Loss Drugs – Will They also Make You Lose Sleep
5. What happens when Medications go wrong?
6. Medications to Prevent Relapse to Cocaine Use
7. More Elderly Take Inappropriate and Harmful Medications
8. Medications for depression
9. Medications linked to xerostomia and caries
10. Medication recuperates fat distribution in diabetes
11. Pharmacist’s Role in Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/27/2017)... MD (PRWEB) , ... July 27, 2017 , ... ... Teams of entrepreneurs will compete to form startup companies around 117 breakthrough inventions ... Heart, Lung, and Blood Institute, and National Institute of Biomedical Imaging and Bioengineering), ...
(Date:7/27/2017)... ... July 27, 2017 , ... Cremations recently surpassed traditional burials ... Association, this trend is expected to continue with over 70% of Americans projected to ... demand for new innovations that enable families to celebrate the life of a lost ...
(Date:7/26/2017)... ... 2017 , ... An inventor from Salisbury, N.C., knows the difficulties involved with ... and dignified way to keep leeches in place during therapy," she said. "That’s why ... an effective way to keep a leech in place on the skin during therapy. ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... Management Solutions as part of their continued efforts to provide innovative offerings to ... the best IT resources and build dynamic, high-performing teams to address healthcare IT’s ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
Breaking Medicine Technology: